Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.
Vlad RatziuSven FrancqueCynthia A BehlingVanja CejvanovicHelena Cortez-PintoJanani S IyerNiels KrarupQuang LeAnne-Sophie SejlingDina TiniakosStephen A HarrisonPublished in: Hepatology (Baltimore, Md.) (2023)
ML categorical assessments reproduced pathologists' results of histological improvement with semaglutide for steatosis and disease activity. ML-based continuous scores demonstrated an antifibrotic effect not measured by conventional histopathology.
Keyphrases
- artificial intelligence
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- machine learning
- big data
- ankylosing spondylitis
- deep learning
- juvenile idiopathic arthritis
- insulin resistance
- high fat diet
- randomized controlled trial
- ultrasound guided
- type diabetes
- high fat diet induced
- clinical trial
- placebo controlled